Skip to main content
NewslettersWatchlist

Aurinia Pharm Ord(AUPH-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low7.32
Day High7.57
Open:7.45
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Business Wire
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
The Globe and Mail
Friday’s analyst upgrades and downgrades
The Globe and Mail
Market movers: Stocks seeing action on Thursday - and why
GlobeNewswire
Kane Biotech Announces Special Meeting of Shareholders
Motley Fool
Why Aurinia Pharmaceuticals Stock Is Slumping Today
Motley Fool
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
Barchart
S&P Futures Climb Ahead of Key U.S. Inflation Data
Business Wire
MKT Capital Issues Statement Regarding Aurinia’s Disappointing First Quarter 2023 Financial Results
Business Wire
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
Business Wire
ISS Recommends Aurinia Shareholders Vote Against the Company’s Named Executive Officers’ Compensation
Business Wire
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
Business Wire
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
Business Wire
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
Business Wire
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
Motley Fool
3 Biotechs That Might Get Bought Out in 2023
Business Wire
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
Business Wire
MKT Capital Issues Letter to Aurinia Shareholders Announcing its Intention to Withhold Support for Three Directors at 2023 Annual Meeting
Business Wire
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
Motley Fool
Why Aurinia Pharmaceuticals Stock Is Glowing Green Today
Business Wire
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
Motley Fool
3 Stocks That Already Doubled in 2023 and Could Keep Climbing
Business Wire
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial

Profile

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.